These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18922900)

  • 1. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
    Miller JK; Shattuck DL; Ingalla EQ; Yen L; Borowsky AD; Young LJ; Cardiff RD; Carraway KL; Sweeney C
    Cancer Res; 2008 Oct; 68(20):8286-94. PubMed ID: 18922900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.
    Shattuck DL; Miller JK; Laederich M; Funes M; Petersen H; Carraway KL; Sweeney C
    Mol Cell Biol; 2007 Mar; 27(5):1934-46. PubMed ID: 17178829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
    Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
    J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
    Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
    Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-opted integrin signaling in ErbB2-induced mammary tumor progression.
    Carraway KL; Sweeney C
    Cancer Cell; 2006 Aug; 10(2):93-5. PubMed ID: 16904607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
    Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
    Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss.
    Lozy F; Cai-McRae X; Teplova I; Price S; Reddy A; Bhanot G; Ganesan S; Vazquez A; Karantza V
    Autophagy; 2014 Apr; 10(4):662-76. PubMed ID: 24492513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
    Tan M; Li P; Sun M; Yin G; Yu D
    Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S; Huang X; Lee CK; Liu B
    Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.
    Yamaguchi N; Oyama T; Ito E; Satoh H; Azuma S; Hayashi M; Shimizu K; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Ohwada S; Tatsuta K; Inoue J; Semba K; Watanabe S
    Cancer Res; 2008 Mar; 68(6):1881-8. PubMed ID: 18339869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
    Spangenberg C; Lausch EU; Trost TM; Prawitt D; May A; Keppler R; Fees SA; Reutzel D; Bell C; Schmitt S; Schiffer IB; Weber A; Brenner W; Hermes M; Sahin U; Türeci O; Koelbl H; Hengstler JG; Zabel BU
    Cancer Res; 2006 Apr; 66(7):3715-25. PubMed ID: 16585198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
    Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
    Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
    Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
    Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.
    Allen-Petersen BL; Carter CJ; Ohm AM; Reyland ME
    Oncogene; 2014 Mar; 33(10):1306-15. PubMed ID: 23474764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
    Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
    Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.